Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine
Retrieved on:
Thursday, June 3, 2021
The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxions AI powered vaccine design platform, along with Evaxions proprietary Antigen Presenting Cell (APC) targeting DNA vaccine technology and novel manufacturing approaches.
Key Points:
- The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxions AI powered vaccine design platform, along with Evaxions proprietary Antigen Presenting Cell (APC) targeting DNA vaccine technology and novel manufacturing approaches.
- The RAVEN platform, an integral part of Evaxions AICoV program, combines advanced algorithms from Evaxions proprietary AI-immunology Core technology to identify optimal T and B cell antigen targets for the development of novel viral vaccines.
- Early data demonstrate that RAVEN identifies novel immunogenic T cell epitopes outside the spike protein, showing RAVENs potential to rapidly support the design of novel SARS-COV-2 vaccines against current and future variants.
- In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.